A Phase 1 Dose Finding Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) in Patients With Relapsed/Refractory, Diffuse Large B-cell Lymphoma, Not Eligible for Autologous Stem Cell Transplant

Trial Profile

A Phase 1 Dose Finding Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) in Patients With Relapsed/Refractory, Diffuse Large B-cell Lymphoma, Not Eligible for Autologous Stem Cell Transplant

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Acronyms LYMRIT-37-05
  • Sponsors Nordic Nanovector
  • Most Recent Events

    • 17 Mar 2017 According to a Nordic Nanovector media release, the first patient has been dosed in the study.
    • 25 Oct 2016 Status changed from not yet recruiting to recruiting.
    • 19 May 2016 According to a Nordic Nanovector media release, the company has received clearance of the Investigational New Drug (IND) Application from the FDA and acceptance of the protocol design from EU Authorities.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top